In: Cancer Immunology, Immunotherapy, 2015, vol. 64, no. 8, p. 1033-1046
|
In: Human reproduction update, ///-
|
In: Glycobiology, 2018, vol. 28, no. 9, p. 640-647
|
In: Glycobiology, 2018, vol. 28, no. 9, p. 638-639
|
In: PLOS ONE, 2020, vol. 15, no. 12, p. e0241500
The presence of ascites in the peritoneal cavity leads to morphological and functional changes of the peritoneal mesothelial cell layer. Cells loose cell-cell interactions, rearrange their cytoskeleton, activate the production of fibronectin, and change their cell surface morphology in a proinflammatory environment. Moreover, ovarian cancer cell adhesion has been shown to be facilitated by...
|
In: International Journal of Molecular Sciences, 2020, vol. 21, no. 12, p. 4441
In recent years, immunotherapy has become the most promising therapy for a variety of cancer types. The development of immune checkpoint blockade (ICB) therapies, the adoptive transfer of tumor-specific T cells (adoptive cell therapy (ACT)) or the generation of T cells engineered with chimeric antigen receptors (CAR) have been successfully applied to elicit durable immunological responses in...
|
In: Scientific Reports, 2020, vol. 10, no. 1, p. 7078
Immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), have resulted in unprecedented improvements in survival for patients with lung cancer. Nonetheless, not all patients benefit equally and many issues remain unresolved, including the mechanisms of action and the possible effector function of immune cells from non-lymphoid lineages. The purpose of this...
|
In: European Journal of Pharmaceutics and Biopharmaceutics, 2019, vol. 139, p. 253–261
Resiquimod (R848), a member of the imidazoquinoline family, is a Toll-like receptor 7/8 agonist with high potency for cancer immunotherapy. However, tolerance induction and adverse effects limit its development as a drug. Encapsulation in a polymer matrix can circumvent these limitations, as shown in our formerly published approach where R848 was loaded into polylactic acid (PLA)-based...
|
In: Cancer Immunology, Immunotherapy, 2014, vol. 63, no. 9, p. 925-938
|
In: Cancer Immunology, Immunotherapy, 2014, vol. 63, no. 3, p. 247-257
|